Travere Therapeutics, Inc.
TVTXHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeTravere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company carries a $4.66B market cap, placing it firmly in the mid-cap category. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Market Cap
$4.66B
Beta
1.14
P/E (TTM)
—
P/E (Fwd)
8.78
EPS (TTM)
$-0.74
EPS (Fwd)
$5.70
ROE
-236.4%
ROA
-3.7%
Cash
$489.2M
Total Debt
$616.9M
Free CF
-$18.3M
52W Change
68.2%
Annual Financials
Cash vs Debt
Where TVTX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TVTX finished 1.08% below its 150-day moving average ($51.04) and 10.05% above its 200-day moving average ($45.88). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TVTX overbought or oversold?
At the October 20, 2026 close, TVTX's RSI(14) was 20.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Travere Therapeutics, Inc. carries $616.9M in total debt against $489.2M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$18.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -236.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $109.5M (2022) to $490.7M (2025), reflecting a 348% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing TVTX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.